Summit Therapeutics (SMMT) has moved higher on investor attention after starting a multiregional Phase II trial of ivonescimab in previously untreated advanced clear cell renal cell carcinoma, expanding the drug’s reach beyond its existing programs.
Recent trading has been choppy for Summit Therapeutics, with the share price down 4.8% over the last day and 18.0% over the past month, and the year-to-date share price return lower by 16.5%. This comes despite a very large three-year total shareholder return of more than 7x, suggesting long-term holders are sitting on substantial gains while near term momentum has faded.
Scan how Summit Therapeutics compares to other high-upside plays in biotech by reviewing our hand picked 20 high quality undiscovered gems with strong fundamentals and under the radar potential.
Summit Therapeutics now trades at a steep discount to prevailing analyst targets after this pullback. Is that gap compensation for real trial and funding risks, or has caution pushed the valuation too far?
Most Popular Narrative: 51% Undervalued
At a last close of $14.63 versus a narrative fair value of about $30.07, Summit Therapeutics is priced well below what the prevailing story assumes.
The breadth of ivonescimab clinical activity across at least 15 Phase III trials and more than 4,000 treated patients positions Summit to participate in the long term shift toward combination immuno oncology and anti angiogenic regimens in multiple tumor types, which is most relevant for potential future revenue growth.
See why 4 investors see Summit Therapeutics as 51% undervalued.
Result: Fair Value of $30.07 (UNDERVALUED)
Still, the whole Summit Therapeutics story leans heavily on a single drug and big late stage trials, so any regulatory setback or weaker data could quickly challenge this undervaluation case.
Find out about the key risks to this Summit Therapeutics narrative.
Another View: What Multiples Say About Summit Therapeutics
The DCF style narrative suggests Summit Therapeutics looks cheap relative to long range cash flow potential. The simple P/B comparison tells a very different story. At 18.6x book value versus 1.8x for the US biotech group and 7.1x for peers, the stock already prices in a lot of future success. If the market leans back toward those lower benchmarks, it is worth asking how much valuation risk you are really comfortable carrying.
For a closer look at how this valuation compares with fundamentals and peers, take a moment to See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
Mixed feelings on Summit Therapeutics after this pullback are understandable. Move quickly and inspect both sides of the ledger for yourself, starting with 2 key rewards and 3 important warning signs.
Looking For More Investment Ideas Beyond Summit Therapeutics?
If you are serious about sharpening your portfolio, do not stop with Summit Therapeutics. Use focused screens to spot opportunities others have not even started researching.
- Target potential mispricings by scanning a curated set of 33 high quality undervalued stocks that combine quality fundamentals with room for sentiment to catch up.
- Strengthen your income stream by reviewing a hand picked pool of 8 dividend fortresses built around higher yields with a focus on resilience.
- Dial down portfolio stress by filtering for 32 resilient stocks with low risk scores that score well on financial stability while still offering meaningful upside potential.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com